Research Article

A case report of an Erdheim-Chester patient focused on pain management

Jose Osvaldo Barbosa Neto*, Joao Batista Santos Garcia, Thiago Alves Rodrigues and Camila Freitas de Andrade Rodrigues

Published: 09/12/2019 | Volume 3 - Issue 1 | Pages: 060-063


Introduction: Erdheim-Chester disease (ECD) is a rare and diffi cult-to-treat non-Langerhans cell histiocytosis characterized by the excessive production and accumulation of histiocytes. This study reports a case of ECD, emphasizing both its diagnosis, assessment and treatment of the
pain associated with the disease.

Case Report: Six years ago, a 39-year-old male patient presented with generalized pain of moderate intensity in the lower limbs that involved periods of greater intensity associated with ambulation. The diagnosis of histiocytosis associated with panhypopituitarism and adrenal insufficiency was proposed. For a specific diagnosis, a bone lesion biopsy was performed, revealing the presence of histiocytic proliferation that was CD1 negative, S100 protein positive, and CD68 negative. Therefore, the diagnosis of non-Langerhans histiocytosis known as ECD was confirmed. During the two years that followed, the patient presented with severe bone pain, particularly in the lower limbs and cranial vault, and the pain subsided to a certain extent with the use of tramadol and paracetamol. Because of the pain, the patient was unable to walk and became bedridden As the patient remained in severe pain, even after the administration of morphine, the opioid was changed from morphine (60mg/day) to oxycodone (30mg/day) for a convenient dosing schedule; furthermore, the oxycodone dosage was scheduled to increase to 40mg/day that same week. The patient experienced significant pain reduction, requiring rescue analgesia only once or twice a week.

Conclusion: To the best of our knowledge, this is the first case report on the characterization and treatment of pain specific to ECD, and we highlight that the patient had a good response to treatment.

Read Full Article HTML DOI: 10.29328/journal.jhcr.1001013 Cite this Article


  1. Mazor RD, Manevich-Mazor M, Shoenfeld Y. Erdheim-Chester Disease: a comprehensive review of the literature. Orphanet J Rare Dis. 2013; 8: 137. PubMed:  
  2. Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol. 2012; 24: 53-59. PubMed:  
  3. Braiteh F, Boxrud C, Esmaeli B, Kurzrock R. Successful treatment of Erdheim-Chester disease, a non–Langerhans-cell histiocytosis, with interferon-α. Blood, 2005;106: 2992-2994. PubMed:  
  4. Dagna L, Girlanda S, Langheim S, Rizzo N, Bozzolo EP, et al. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology. 2010; 49: 1203-1206. PubMed:  
  5. Quran S, Reith J, Bradley J, Rimsza L. Erdheim-Chester disease: case report, PCR-based analysis of clonality, and review of literature. Mod Pathol. 2002; 15: 666-672. PubMed:  
  6. Murray D, Marshall M, England E, Mander J, Chakera TM. Erdheim-chester disease. Clin Radiol. 2001; 56: 481-484. PubMed:  
  7. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D. Erdheim-Chester disease: Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore). 1996; 75: 157-169. PubMed:  
  8. Luft T, Pang KC, Thomas E. Type I interferons enhance the terminal differentiation of dendritic cells. J Immunol. 1998; 161: 1947-1953. PubMed:  
  9. Luft T, Luetjens P, Hochrein H. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol. 2002; 14: 367-380. PubMed:  
  10. Chester W. Über lipoidgranulomatose (Over lipoid granulomatosis). Virchows Arch Pathol Anat Physiol. 1930; 279: 561-602.
  11. Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol. 2012; 24: 53-59. PubMed:  
  12. Haroche J, Arnaud L, Cohen-Aubart F, Hervier B, Charlotte F, et al. Erdheim-Chester disease. Rheum Dis Clin North Am. 2013; 39: 299-311. PubMed:  
  13. Kornik RI, Naik HB, Lee CC, Estrada-Veras J, Gahl WA, et al. Diabetes insipidus, bone lesions, and new-onset red-brown papules in a 42-year-old man. J Am Acad Dermatol. 2013; 68: 1034-1038. PubMed:  
  14. Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, et al. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis. 2013; 72: 1691-1695.
  15. Steinert AF, Reppenhagen S, Baumann B, Rudert M, Nöth U. Total knee arthroplasty in a patient with Erdheim-Chester disease with massive joint destruction: a case report. J Bone Joint Surg Am. 2011; 93: e29. PubMed:  
  16. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res. 2005; 15: 57-62. PubMed:  
  17. Buga S, Sarria JE. The management of pain in metastatic bone disease. Cancer Control. 2012; 19: 154-166. PubMed:  
  18. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, et al. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain. Eur J Neurol. 2010; 17: 1113-1188.
  19. Nascimento D, Pozza DH, Castro-Lopes JM, Neto FL. Neuronal injury marker ATF-3 is induced in primary afferent neurons of monoarthritic rats. Neurosignals. 2011; 19: 210-221. PubMed:  
  20. Ivanavicius SP, Ball AD, Heapy CG, Westwood FR, Murray F, et al. Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation. Pain. 2007; 128: 272-282.